Cargando…

Beyond Adding Years to Life: Health-related Quality-of-life and Functional Outcomes in Patients with Severe Aortic Valve Stenosis at High Surgical Risk Undergoing Transcatheter Aortic Valve Replacement

Aortic valve stenosis (AVS) is the most frequent acquired valvular heart disease in western industrialized countries and its prevalence considerably increases with age. Once becoming symptomatic severe AVS has a very poor prognosis. Progressive and rapid symptom deterioration leads to an impairment...

Descripción completa

Detalles Bibliográficos
Autores principales: Deutsch, Marcus-André, Bleiziffer, Sabine, Elhmidi, Yacine, Piazza, Nicolo, Voss, Bernhard, Lange, Ruediger, Krane, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941091/
https://www.ncbi.nlm.nih.gov/pubmed/24313648
http://dx.doi.org/10.2174/1573403X09666131202121750
_version_ 1782305867401527296
author Deutsch, Marcus-André
Bleiziffer, Sabine
Elhmidi, Yacine
Piazza, Nicolo
Voss, Bernhard
Lange, Ruediger
Krane, Markus
author_facet Deutsch, Marcus-André
Bleiziffer, Sabine
Elhmidi, Yacine
Piazza, Nicolo
Voss, Bernhard
Lange, Ruediger
Krane, Markus
author_sort Deutsch, Marcus-André
collection PubMed
description Aortic valve stenosis (AVS) is the most frequent acquired valvular heart disease in western industrialized countries and its prevalence considerably increases with age. Once becoming symptomatic severe AVS has a very poor prognosis. Progressive and rapid symptom deterioration leads to an impairment of functional status and compromised healthrelated quality-of-life (HrQoL) simultaneously. Until recently, surgical aortic valve replacement (SAVR) has been the only effective treatment option for improving symptoms and prolonging survival. Transcatheter aortic valve replacement (TAVR) emerged as an alternative treatment modality for those patients with severe symptomatic AVS in whom the risk for SAVR is considered prohibitive or too high. TAVR has gained clinical acceptance with almost startling rapidity and has even quickly become the standard of care for the treatment of appropriately selected individuals with inoperable AVS during recent years. Typically, patients currently referred for and treated by TAVR are elderly with a concomitant variable spectrum of multiple comorbidities, disabilities and limited life expectancy. Beyond mortality and morbidity, the assessment of HrQoL is of paramount importance not only to guide patient-centered clinical decision-making but also to judge this new treatment modality. As per current evidence, TAVR significantly improves HrQoL in high-surgical risk patients with severe AVS with sustained effects up to two years when compared with optimal medical care and demonstrates comparable benefits relative to SAVR. Along with a provision of a detailed overview of the current literature regarding functional and HrQoL outcomes in patients undergoing TAVR, this review article addresses specific considerations of the HrQoL aspect in the elderly patient and finally outlines the implications of HrQoL outcomes for medico-economic deliberations.
format Online
Article
Text
id pubmed-3941091
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-39410912014-11-01 Beyond Adding Years to Life: Health-related Quality-of-life and Functional Outcomes in Patients with Severe Aortic Valve Stenosis at High Surgical Risk Undergoing Transcatheter Aortic Valve Replacement Deutsch, Marcus-André Bleiziffer, Sabine Elhmidi, Yacine Piazza, Nicolo Voss, Bernhard Lange, Ruediger Krane, Markus Curr Cardiol Rev Article Aortic valve stenosis (AVS) is the most frequent acquired valvular heart disease in western industrialized countries and its prevalence considerably increases with age. Once becoming symptomatic severe AVS has a very poor prognosis. Progressive and rapid symptom deterioration leads to an impairment of functional status and compromised healthrelated quality-of-life (HrQoL) simultaneously. Until recently, surgical aortic valve replacement (SAVR) has been the only effective treatment option for improving symptoms and prolonging survival. Transcatheter aortic valve replacement (TAVR) emerged as an alternative treatment modality for those patients with severe symptomatic AVS in whom the risk for SAVR is considered prohibitive or too high. TAVR has gained clinical acceptance with almost startling rapidity and has even quickly become the standard of care for the treatment of appropriately selected individuals with inoperable AVS during recent years. Typically, patients currently referred for and treated by TAVR are elderly with a concomitant variable spectrum of multiple comorbidities, disabilities and limited life expectancy. Beyond mortality and morbidity, the assessment of HrQoL is of paramount importance not only to guide patient-centered clinical decision-making but also to judge this new treatment modality. As per current evidence, TAVR significantly improves HrQoL in high-surgical risk patients with severe AVS with sustained effects up to two years when compared with optimal medical care and demonstrates comparable benefits relative to SAVR. Along with a provision of a detailed overview of the current literature regarding functional and HrQoL outcomes in patients undergoing TAVR, this review article addresses specific considerations of the HrQoL aspect in the elderly patient and finally outlines the implications of HrQoL outcomes for medico-economic deliberations. Bentham Science Publishers 2013-11 2013-11 /pmc/articles/PMC3941091/ /pubmed/24313648 http://dx.doi.org/10.2174/1573403X09666131202121750 Text en © 2013 Bentham Science Publishers http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Deutsch, Marcus-André
Bleiziffer, Sabine
Elhmidi, Yacine
Piazza, Nicolo
Voss, Bernhard
Lange, Ruediger
Krane, Markus
Beyond Adding Years to Life: Health-related Quality-of-life and Functional Outcomes in Patients with Severe Aortic Valve Stenosis at High Surgical Risk Undergoing Transcatheter Aortic Valve Replacement
title Beyond Adding Years to Life: Health-related Quality-of-life and Functional Outcomes in Patients with Severe Aortic Valve Stenosis at High Surgical Risk Undergoing Transcatheter Aortic Valve Replacement
title_full Beyond Adding Years to Life: Health-related Quality-of-life and Functional Outcomes in Patients with Severe Aortic Valve Stenosis at High Surgical Risk Undergoing Transcatheter Aortic Valve Replacement
title_fullStr Beyond Adding Years to Life: Health-related Quality-of-life and Functional Outcomes in Patients with Severe Aortic Valve Stenosis at High Surgical Risk Undergoing Transcatheter Aortic Valve Replacement
title_full_unstemmed Beyond Adding Years to Life: Health-related Quality-of-life and Functional Outcomes in Patients with Severe Aortic Valve Stenosis at High Surgical Risk Undergoing Transcatheter Aortic Valve Replacement
title_short Beyond Adding Years to Life: Health-related Quality-of-life and Functional Outcomes in Patients with Severe Aortic Valve Stenosis at High Surgical Risk Undergoing Transcatheter Aortic Valve Replacement
title_sort beyond adding years to life: health-related quality-of-life and functional outcomes in patients with severe aortic valve stenosis at high surgical risk undergoing transcatheter aortic valve replacement
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941091/
https://www.ncbi.nlm.nih.gov/pubmed/24313648
http://dx.doi.org/10.2174/1573403X09666131202121750
work_keys_str_mv AT deutschmarcusandre beyondaddingyearstolifehealthrelatedqualityoflifeandfunctionaloutcomesinpatientswithsevereaorticvalvestenosisathighsurgicalriskundergoingtranscatheteraorticvalvereplacement
AT bleiziffersabine beyondaddingyearstolifehealthrelatedqualityoflifeandfunctionaloutcomesinpatientswithsevereaorticvalvestenosisathighsurgicalriskundergoingtranscatheteraorticvalvereplacement
AT elhmidiyacine beyondaddingyearstolifehealthrelatedqualityoflifeandfunctionaloutcomesinpatientswithsevereaorticvalvestenosisathighsurgicalriskundergoingtranscatheteraorticvalvereplacement
AT piazzanicolo beyondaddingyearstolifehealthrelatedqualityoflifeandfunctionaloutcomesinpatientswithsevereaorticvalvestenosisathighsurgicalriskundergoingtranscatheteraorticvalvereplacement
AT vossbernhard beyondaddingyearstolifehealthrelatedqualityoflifeandfunctionaloutcomesinpatientswithsevereaorticvalvestenosisathighsurgicalriskundergoingtranscatheteraorticvalvereplacement
AT langeruediger beyondaddingyearstolifehealthrelatedqualityoflifeandfunctionaloutcomesinpatientswithsevereaorticvalvestenosisathighsurgicalriskundergoingtranscatheteraorticvalvereplacement
AT kranemarkus beyondaddingyearstolifehealthrelatedqualityoflifeandfunctionaloutcomesinpatientswithsevereaorticvalvestenosisathighsurgicalriskundergoingtranscatheteraorticvalvereplacement